PLGA Nanoparticles for Photosensitizer Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current delivery systems for photosensitizers in photodynamic therapy face challenges such as high lipophilicity, inadequate activation due to light therapy variability, and non-biodegradable nanoparticles that fail to control compound release, leading to inefficiencies and immunogenicity.
Innovation Solution
Biodegradable polymeric nanoparticles, specifically PLGA nanoparticles encapsulating hypocrellin B or derivatives, which can be activated to generate singlet oxygen using photodynamic therapy, hydrogen peroxide, or their combination, for targeted and controlled delivery to tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-biodegradable nanoparticles are used for photosensitizer delivery, then compound delivery to target tissue is achieved, but the nanoparticles fail to degrade and release compounds in a controlled manner
Solution Approach 1:
The patent changes the chemical composition parameters of the nanoparticle material from non-biodegradable to biodegradable polymers, specifically using poly(lactic-co-glycolic acid) (PLGA) with controlled degradation rates. This allows the nanoparticle to maintain structural integrity for delivery while gradually degrading to release the photosensitizer in a controlled manner.
Solution Approach 2:
The patent creates a composite nanoparticle system combining biodegradable polymer matrix (PLGA) with encapsulated photosensitizer compounds. This composite structure provides both the delivery function of the nanoparticle and the controlled release through polymer degradation, resolving the contradiction between delivery reliability and biodegradability.
2Area of stationary object
If photosensitizers are administered systemically, then broad tissue coverage is achieved, but selective accumulation in target tissue is reduced
Solution Approach 1:
The patent applies local quality by functionalizing the nanoparticle surface with targeting moieties (such as antibodies, peptides, or ligands) that specifically recognize receptors on target tissue cells. This allows systemic administration for broad coverage while achieving selective accumulation at the target site through localized molecular interactions.
Solution Approach 2:
The nanoparticle acts as an intermediary carrier that bridges systemic administration and target-specific delivery. The surface-modified nanoparticle mediates between the bloodstream and target tissue, enabling both broad distribution and selective uptake through receptor-mediated endocytosis or other targeted mechanisms.
3Power
If light therapy is used to activate photosensitizers, then singlet oxygen generation is achieved, but activation consistency varies due to light therapy variability
Solution Approach 1:
The patent employs photosensitizers with self-quenching properties that automatically regulate their activation. When excited by light, the photosensitizer generates singlet oxygen but also undergoes self-quenching that prevents over-activation. This self-regulating mechanism provides more consistent and reliable activation compared to externally controlled light therapy alone.
Solution Approach 2:
The patent utilizes the periodic nature of photosensitizer excitation and self-quenching cycles. The photosensitizer alternates between active singlet oxygen generation states and self-quenched inactive states, creating a self-regulating periodic action that ensures consistent activation without the variability of continuous light exposure.
4Volume of moving object
If nanoparticle size is reduced to 100 nm or less, then volume of distribution equivalent to photosensitizer is achieved, but maximum allowable diameter is severely limited
Solution Approach 1:
The patent changes the size parameter of the nanoparticle to an optimized range of 50-200 nm, balancing the volume of distribution requirement with the need for adequate drug loading capacity. This parameter optimization allows sufficient tissue penetration while maintaining practical nanoparticle functionality for photosensitizer delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PLGA nanoparticles provide efficient, selective accumulation of photosensitizers in diseased tissues with minimal uptake by healthy cells, enabling effective anti-cell proliferation activity and prolonged treatment efficacy without cumulative toxicity.
Implementation Method 1
PDT involves a compound known as a 'photosensitizer' which can be excited or activated in a variety of ways, including, for example, by visible or near infrared light of a specific wavelength. PDT treatment is an oxygen dependent reaction, in which the production of reactive oxygen species causes tissue damage by cellular necrosis or apoptosis.
Implementation Method 2
the photosensitizer, which acts as a catalyst to destroy the target tissue by generating singlet oxygen
Implementation Method 3
Biodegradable nanoparticles are solid colloidal particles formed by the association of suitable polymers. It is known that the chemical composition of such polymers can be readily designed to incorporate compounds with variable degrees of hydrophobicity, molecular weight and charge.
Data Source
AI summary
Biodegradable polymeric nanoparticles comprising an inner core formed of a photodynamic agent capable of being activated to generate cytotoxic singlet oxygen are prepared. These nanoparticles have anti-cell proliferation activity and are useful in treating both cancerous and non-cancerous conditions including actinic keratosis, psoriasis and acne vulgaris. Preferably, the photodynamic agent is a hypocrellin B derivative while the polymeric nanoparticle comprises polyglycolic acid, polylactic acid or poly(lactide-co-glycolide). Hypocrellin-comprising nanoparticles are demonstrated to be activated by light or hydrogen peroxide.